Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Most Americans would prefer brand-name drugs—but end up buying generic versions because of the cost, new consumer research ...

U.S. Senator Tammy Baldwin (D-WI) joined a group of her colleagues in introducing the Capping Prescription Costs Act, ...

Determining the various costs of Medicare can be confusing. There are annual deductibles, monthly premiums and doctor visit ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit these popular categories the hardest.

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Learn how tariffs influence U.S. trade, national security and economic policy. Explore their impact on industries, consumers ...

The Senate confirmed Robert F. Kennedy Jr. as secretary of the Department of Health and Human Services. Healthcare leaders ...

Senator Kirsten Gillibrand announced the Capping Prescription Costs Act, which would limit annual out-of-pocket drug expenses ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.